Investigators to present new study results and discuss clinical benefit
for GI patients with Eosinophilic Esophagitis, IBD, polyps, HIV, spirochetosis
and H. pylori
Findings from seven research studies conducted by the Inform Diagnostics
Research Institute have been selected for presentation at this year’s
American College of Gastroenterology annual scientific meeting. Beginning
Sunday, October 13, 2013 through Tuesday, October 15, attendees at the
San Diego-based meeting will have an opportunity to review these seven
studies, and learn about the specific clinical utility of these investigations
to benefit patient care.
Dr. Robert M. Genta, Chief of Academic Affairs at the Inform Diagnostics
Research Institute and a Clinical Professor of Pathology and Gastroenterology
at the University of Texas Southwestern Medical Center at Dallas, noted
that the studies are based upon data from the company’s extensive
repository of histopathologic, demographic and clinical patient information
and represent important advancements in patient care.
Dr. Genta said, “With more than 5 million patients in our database,
each complete with demographic, endoscopic, and clinical data, we are
in a unique position to carry out nation-wide clinicopathologic research
projects. The studies reported at this year’s meeting, as well as
some studies recently published by Inform Diagnostics pathologists,
are prime examples of the broad cross-section of demographics and disease
states that can lie at the foundation of our research endeavors.”
The seven studies by pathologists at Inform Diagnostics include new insights
suggesting that Eosinophilic Esophagitis and inflammatory bowel disease
(IBD) may share a common immunopathogenetic mechanism; how the role of
HIV infection and CD4 cells affect gastric mucosal response; and strong
data supporting the assertion that
Helicobacter-negative Chronic Active Gastritis occurs as a distinct condition, unrelated to
H. pylori infection.
Another study confirmed the inverse relationship between Eosinophilic Esophagitis
H. pylori infection (previously reported by Lash and Genta from Inform Diagnostics
in collaboration with researcher from the University of North Carolina)
and expanded the observations to other conditions of the stomach, including
autoimmune atrophic gastritis.
The Inform Diagnostics Research Institute efforts, Dr. Genta says, “address
diverse gastroenterological conditions that have widespread prevalence
and incur significant burden to an individual’s quality of life,
and expense to our health system.”
“It is imperative to develop new approaches in diagnosis and therapy.
These can best develop from research that examines large amounts of data
for nuances of pathologic relationships that would be undiscoverable in
small studies, giving us insights to advance quality care and treatment
outcomes in these populations.”
Also to be presented are conclusions from the largest clinicopathologic
series of patients with documented spirochetosis, which found that the
condition may be asymptomatic in more than half of the subjects infected.
Researchers will also discuss the unexpected finding of fungal esophagitis
in patients with endoscopically unremarkable esophagus, and how patients
with diarrhea and microscopic colitis (MC) have a significantly lower
prevalence of colorectal polyps, suggesting inhibition of epithelial proliferation
by regulatory T-cells.
About Inform Diagnostics
Serving more than 3,500 patients each day,
Inform Diagnostics is a leader in providing an academic-caliber pathology laboratory with
diagnostic services in the fields of dermatology, gastroenterology, hematology
and urology. Building upon our experience with health IT, we also offer
accessible technology solutions to assist healthcare professionals as
they work towards accordance with Meaningful Use initiatives.
Inform Diagnostics, a wholly-owned subsidiary of Japan-based Inform Diagnostics Holdings
Inc., employs a talented team of leading pathologists, histologists, lab
technicians, technology consultants, and other medical professionals —
all driven to help provide the highest and most up-to-date levels of diagnostic
quality, enhanced workflow and practice solutions possible. It is part
of our commitment: not only to scientific excellence, but to patients